GlobalDatas pharmaceuticals report, Ellence (Bladder Cancer) Analysis and Forecasts to 2020 provides Ellence EU sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2012). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Ellence including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Ellence including efficacy, safety, pricing, competition and other details which influence its sales potential
• Global sales forecasts for 2002-2012 for Ellence

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drugs performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Report Guidance 7

3 Bladder Cancer Disease: Market Characteristics 8
3.1 Bladder Cancer Disease Market 8
3.2 Bladder Cancer Disease Market Forecasts 8
3.3 Drivers for the Bladder Cancer Disease Market 9
3.3.1 High Prevalence 9
3.3.2 High Incidence 9
3.3.3 High Survival Rate 10
3.3.4 High lifetime costs 11

4 TNM Classification of bladder cancer 12
4.1 American Urological Association 12

5 Ellence 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Ellence 16
5.5 Contraindications 16
5.6 Factors Impacting Sales 16
5.6.1 Bladder Cancer Market Characteristics 16
5.6.2 Moderate Efficacy 16
5.6.3 Poor Safety Profile 17
5.6.4 Competition 17
5.7 Drug Risk Benefit Score (DRB) 17
5.7.1 Efficacy 18
5.7.2 Safety 18
5.7.3 Compliance 18
5.7.4 Dosing Convenience 18
5.8 Sales forecast 18
5.8.1 Target Patient Pool of Ellence 18
5.8.2 Dosing of Ellence 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Ellence 20

6 Bladder Cancer Market: Appendix 21
6.1 Market Definitions 21
6.2 List of Abberiviations 21
6.3 Research Methodology 21
6.3.1 Coverage 21
6.3.2 Secondary Research 21
6.3.3 Forecasting 22
6.3.4 Number of Patients Approved to take the Drug 22
6.3.5 Net Penetration of Drug 22
6.3.6 Net Annual Dosing 22
6.3.7 Annual Cost of Therapy 23
6.3.8 Primary Research 23
6.3.9 Expert Panels 23
6.4 Contact Us 23
6.5 Disclaimer 23
6.6 Sources 24

List of Tables

Table 1: Bladder Cancer Incidences & Mortality 5
Table 2: Bladder Cancer, Global, Market Forecasts ($bn), 20092020 9
Table 3: Drug Approval , Expiry and Indications 16
Table 4: Drug Risk Benefit Score 17
Table 5: Dosage 19

List of Figures

Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage share of risk factors in Developed Countries 6
Figure 4: Percentage share of risk factors in Developing Countries 6
Figure 5: Smoking Consumption Curve, US,1960-2006 6
Figure 6: Bladder Cancer, Global, Market Size Forecasts ( $bn) , 2009-2020 9
Figure 7: Oncology, Worldwide, Estimated Incidence 2008-2030 10
Figure 8: Bladder Cancer, Worldwide, Estimated Incidence 2008-2030 10
Figure 9: Broad Classification of Bladder Cancer 12
Figure 10: Classification of NMI Bladder Cancer 12
Figure 11: Detailed TNM Classifications 13
Figure 12: Classification of NMI Bladder Cancer 14
Figure 13: Ellence Drug Model Diagram 19
Figure 14: Bladder Cancer, EU, Sales Forecasts for Ellence ( $m), 2002-2012 20